Shame on you, Al
It's very difficult to understand how SNY could end up with a drug that they have tanked, but it really may come down to their best overall interests with regard to Afrezza/GLP-1 inhalers.
Afrezza is worth at least $2b as a niche drug today. And we know SNY spent upfront money on 2 different GLP-1 drugs.
Stock price smells.
All of this nonsense so that SNY could buy Afrezza and GLP-1 for $12/share while GreenHILL/Deerfield buddies made bank on the short and the killed options.....GROSS.....SHAME ON YOU AL
Fraggy finally read the FDA trials. Bmcgoo still hasn't realized that SNY has worldwide rights until #4516,
Somebody thinks $150m upfront for India Afrezza license when they only got $150m for worldwide rights.
Habusa says $50. Kevin found the name of a Chinaman so Bill Gates must be involved.
Lanafischer babbling to anyone who will listen on Twitter
Take a break. Watch a film. Get a good night's rest and THEN contribute something... anything.
You only need to model it for 0.5% to show how ridiculously cheap we are trading
This is to acknowledge that the Market Regulation Department of the Financial Industry Regulatory Authority (FINRA) received your website complaint regarding trading activity in MannKind Corporation (“MNKD”) from August 1, 2014 through January 20, 2016. We will use the information you provided regarding MNKD in the scope of our regulatory programs designed to determine whether violations of federal securities laws or FINRA or other rules have occurred. While the reviews conducted by the Market RegulationDepartment are confidential and non-public, the staff may contact you if deemed appropriate as it carries out its responsibilities with regard to your concerns.
Today's CC included an almost pedantic resume reading by Ray. For whose benefit?
Most of us listened to previous call and got the same slides and info. Seems like Management is still pitching the whole shebang to a 3rd party. Just can't believe that Mnkd is going to actually try the Afrezza thing themselves.... Don't believe it. Afrezza is gone in April and I'll be surprised if TS isn't sold off too
pps moving higher. shorting getting more expensive. GS should be on the call and I fully expect them to raise PT on Friday after CC.
Would think that there would be a PR Perhaps announcing a TS partnership either tomorrow or Wednesday. May get some financing as well....and of course, the elephant in the room....AFREZZA. Will there be a PR related to clinics opening, an overseas sale or approval?
Will we get diluted?
One way or another the stock should respond positively to anything that raises cash.
If they were to purchase more than 5% of MNKD stock, they would be required to report it. They just don't have to report things that are done within RLS.
Take it a little further with regard to Mann's Estate. Do they want to liquidate their investment or leave it in the hands of present management?
Hard to believe that they want to see Matt and Ray going it alone for Afrezza when even a lowball offer for Danbury and Afrezza would be worth $2-3b essentially tax free so the cash position would be worth about $8-10 per share after paying off ALL debt.
Stock could then move on TS developments alone.
Matt is a biotech guy and MNKD is a biotech company.
With Afrezza gone, they can use the money to develop in house TS projects for years and potentially sign better deals for drugs that have passed the early development stages successfully.
That still doesn't get Mann's Estate a single cent and I think they will entertain scenarios that allows them to extract capital from the company NOW rather than risk putting more in at this time.
Perhaps a one-time dividend to shareholders or an Afrezza-partner BP stock and cash deal that at the very least would diversify the Mann Estate's holdings to be less MNKD-weighted.